^
almost2years
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (clinicaltrials.gov)
P1, N=9, Completed, Baylor College of Medicine | Active, not recruiting --> Completed | Trial completion date: Oct 2036 --> Jan 2023
Trial completion • Trial completion date
|
GPC3 (Glypican 3)
|
GPC3 positive
|
cyclophosphamide • fludarabine IV • GLYCAR T cells
over2years
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (clinicaltrials.gov)
P1, N=9, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=14 --> 9
Enrollment closed • Enrollment change
|
GPC3 (Glypican 3)
|
GPC3 positive
|
cyclophosphamide • fludarabine IV • GLYCAR T cells
over4years
A Phase 1 Clinical Trial Using Armored GPC3-Car T Cells for Children with Relapsed/ Refractory Liver Tumors (ASGCT 2020)
The initial results from this clinical trial show that GPC3-CAR T cells are well tolerated and have anti-tumor activity in children with liver tumors.
Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
|
CD8 (cluster of differentiation 8) • GPC3 (Glypican 3)
|
GLYCAR T cells